Clinical Trial Update: A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma [Phase 2]

View source ↗

Summary

DS-1001b is a Phase 2 study in IDH1-mutated, chemo- and radiotherapy-naive WHO Grade II glioma. The trial is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low-grade Glioma

Drugs mentioned

• DS-1001b

Snippet

Sponsor: Daiichi Sankyo Co., Ltd. | Conditions: WHO Grade II Glioma | Phase 2 | Status: ACTIVE_NOT_RECRUITING